ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/MEK-inhibitor

Search results

target/MEK-inhibitor
10 trial(s) found.
NCT07562152
NCT06804824
NCT06326411
NCT06072781
NCT05538130
NCT05203172
NCT03975829
NCT03947385
NCT05182931
NCT03363867
Filters
MEK
90%
BRAF
60%
RAF
60%
BRAF V600
30%
CRAF
20%
pan-RAF
20%
ERBB2
10%
HRAS
10%
HRAS G12C
10%
KRAS
10%
KRAS G12C
10%
NRAS
10%
NRAS G12C
10%
PI3Kalpha
10%
FAK
10%
oestrogen axis
10%
CDK4
10%
CDK6
10%
EGFR
10%
ALK
10%
MET
10%
PKC
10%
ROS1
10%
PD-1/PD-L1
10%
PD-L1
10%
VEGF
10%




















 






























	
		
	

    

        

			ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

			
    
			
  • Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
    • 
			
			
  • Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
    • 
			
			
  • No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
    • 
			
			
  • External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.
    • 
			
			


			By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.
			
		

        

            
The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

            
            
Users are free to:

            
    
                
  • Share — copy and redistribute the data in any medium or format
    • 
                
  • Adapt — remix, transform, and build upon the data
    • 
                
  • Use the data for any purpose, including commercial use
    • 
            

            
            
Under the following terms:

            
    
                
  • Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
    • 
                
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
    • 
            

            
            
Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.